Resources - Brukinsa®▼ (zanubrutinib)

WM Educational materials video

Date of preparation: August 2023. 0223-BRU-PRC-097

BRUKINSA WM NICE Approval Discussion

Date of preparation: September 2022. 0922-BRU-PRC-084

Diagnosis, Clinical Features and Indications for WM Therapy

Date of preparation: November 2022. 1122-BRU-PRC-051

An In-Depth Look at the ASPEN Study – Dr Roger Owen and Dr Shirley D’Sa

Date of preparation: November 2022. 1122-BRU-PRC-100

Practical Considerations of BRUKINSA – Dr Jaimal Kothari

Date of preparation: November 2022. 1122-BRU-PRC-102

Current Treatments: BSH Guidelines – Dr Dima El-Sharkawi

Date of preparation: November 2022. 1122-BRU-PRC-097

Welcome to “Real world experience treating WM and what’s next for CLL” – Dr Robert Mulrooney

Date of preparation: July 2023. 0723-BRU-PRC-076

Waldenström’s macroglobulinaemia/ lymphoplasmacytic lymphoma: An introduction – Prof George Follows

Date of preparation: July 2023. 0723-BRU-PRC-077

Case-based panel discussion – Dr Pam McKay

Date of preparation: July 2023. 0723-BRU-PRC-078

Case-based panel discussion – Dr Sarah Lawless

Date of preparation: July 2023. 0723-BRU-PRC-079

Case-based panel discussion – Dr Vishal Jayakar

Date of preparation: July 2023. 0723-BRU-PRC-080

Closing

Date of preparation: July 2023. 0723-BRU-PRC-082

The Changing Landscape of WM in Scotland with Dr Pam McKay

Date of preparation: November 2022. 1122-BRU-PRC-067

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at https://yellowcard.mhra.gov.uk/.
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA at www.HPRA.ie.

All adverse events (UK and Ireland) should also be reported to BeiGene at adverse_events@beigene.com; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: medicalinformationEU@beigene.com

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

October 2023 [0823-BRU-PRC-171]

Resources Waldenström’s macroglobulinaemia (WM)